Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 + Pyrotinib in HER2 Insertion Mutation Advanced NSCLC
NCT04144569Phase 2Recruiting
- Sponsor
- Yongchang Zhang
- Start
- Jan 2019
- Primary completion
- Dec 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib in non-small cell lung cancer (NSCLC), sponsored by Yongchang Zhang. Started Jan 2019; status: recruiting.
02
Drugs
pyrotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04144569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04144569.